Published in Cochrane Database Syst Rev on January 24, 2007
Finasteride reduces the risk of incident clinical benign prostatic hyperplasia. Eur Urol (2012) 1.89
When not to use beta-blockers in seniors with hypertension. J Fam Pract (2008) 1.37
Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis. BMC Med (2012) 1.15
Newer is not always better: all antihypertensive medications do not equally reduce cardiovascular risk. J Gen Intern Med (2012) 0.94
Use of carvedilol in hypertension: an update. Vasc Health Risk Manag (2012) 0.92
Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects. Am Heart J (2011) 0.90
Physician and patient influences on provider performance: β-blockers in postmyocardial infarction management in the MI-Plus study. Circ Cardiovasc Qual Outcomes (2010) 0.87
High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy. Circulation (2015) 0.86
Beta-Blockers in the Management of Hypertension and/or Chronic Kidney Disease. Int J Hypertens (2014) 0.84
Prevalence and risk factors for resistant hypertension among hypertensive patients from a developing country. BMC Res Notes (2013) 0.83
Beta-blockers and the treatment of hypertension: it is time to move on. Cardiovasc J Afr (2007) 0.81
Comparative effectiveness of 2 β-blockers in hypertensive patients. Arch Intern Med (2012) 0.80
Hypertension, the changing pattern of drug usage. Cardiovasc J Afr (2009) 0.78
Cost implications of improving blood pressure management among U.S. adults. Health Serv Res (2011) 0.77
Nonselective β-blocker propranolol for orbital and periorbital hemangiomas in infants: a new first-line of treatment? Clin Ophthalmol (2011) 0.77
Review: Available evidence does not support the use of beta blockers as first line treatment for hypertension. Evid Based Med (2007) 0.76
Hypertension management: an update. Am Health Drug Benefits (2010) 0.75
[Beta-blockers as first-line therapy for hypertension?]. Dtsch Med Wochenschr (2013) 0.75
Observational comparative effectiveness studies of drug therapies: high-quality answers or important clinical questions?: comment on "Comparative effectiveness of 2 β-blockers in hypertensive patients". Arch Intern Med (2012) 0.75
Clinical trials of antihypertensives: Nature of control and design. Indian J Pharmacol (2011) 0.75
Chronic β1-adrenoceptor blockade impairs ischaemic tolerance and preconditioning in murine myocardium. Eur J Pharmacol (2016) 0.75
HIV and male circumcision--a systematic review with assessment of the quality of studies. Lancet Infect Dis (2005) 3.49
The activities of fructose 1,6-diphosphatase, phosphofructokinase and phosphoenolpyruvate carboxykinase in white muscle and red muscle. Biochem J (1967) 3.14
Celecoxib--is it worth celebrating? S Afr Med J (2000) 3.01
Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev (2004) 2.95
Tracking myocardial motion from cine DENSE images using spatiotemporal phase unwrapping and temporal fitting. IEEE Trans Med Imaging (2007) 2.55
Effects of insulin on the pattern of glucose metabolism in the perfused working and Langendorff heart of normal and insulin-deficient rats. Biochem J (1969) 2.46
Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev (2003) 2.32
South African hypertension guideline 2006. S Afr Med J (2006) 2.23
Sudden death and sport. Lancet (1975) 2.14
Effects of increased heart work on glycolysis and adenine nucleotides in the perfused heart of normal and diabetic rats. Biochem J (1971) 2.04
Drugs and the heart. III. Calcium antagonists. Lancet (1980) 1.99
Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet (1994) 1.99
Depression and anxiety as predictors of outcome after myocardial infarction. Psychosom Med (2000) 1.81
Atenolol plus nifedipine for mild to moderate systemic hypertension after fixed doses of either agent alone. Am J Cardiol (1986) 1.75
Genetically determined factors as predictors of radiological change in patients with early symmetrical arthritis. BMJ (1992) 1.72
Nutritional interventions for reducing morbidity and mortality in people with HIV. Cochrane Database Syst Rev (2007) 1.71
Relation between plasma free fatty acids and arrhythmias within the first twelve hours of acute myocardial infarction. Lancet (1983) 1.69
Glucose-insulin-potassium (GIK) for acute myocardial infarction: a negative study with a positive value. Cardiovasc Drugs Ther (1999) 1.63
Abnormal sulphur oxidation in systemic lupus erythematosus. Lancet (1992) 1.62
Nifedipine and mortality. Grave defects in the dossier. Circulation (1995) 1.61
Adverse interaction between nifedipine and beta-blockade. Br Med J (1980) 1.60
Metabolism of the heart in health and disease. I. Am Heart J (1968) 1.58
Directly observed therapy. Lancet (1997) 1.48
Genetic factors influencing the outcome of early arthritis--the role of sulphoxidation status. Br J Rheumatol (1992) 1.47
Calcium antagonists. Mechanisms, therapeutic indications and reservations: a review. Q J Med (1984) 1.43
Increased plasma-free-fatty-acid concentrations and their significance in patients with acute myocardial infarction. Lancet (1969) 1.43
DOTS--are we over-optimistic? S Afr Med J (1997) 1.40
Effects of glucose, insulin and potassium infusion on tissue metabolic changes within first hour of myocardial infarction in the baboon. Circulation (1975) 1.39
Protons in ischemia: where do they come from; where do they go to? J Mol Cell Cardiol (1991) 1.39
Effect of oxygenation and consequent pH changes on the efficacy of St. Thomas' Hospital cardioplegic solution. J Thorac Cardiovasc Surg (1991) 1.39
Myocardial blood flow, deoxyglucose uptake, and myocyte viability in ischemia. J Nucl Med (1992) 1.38
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev (2002) 1.31
Characterization of the "border zone" in acute regional ischemia in the dog. Am J Cardiol (1977) 1.28
Antihypertensive effects of nifedipine combined with cardioselective beta-adrenergic receptor antagonism by atenolol. Am Heart J (1982) 1.28
Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction. Relation to myocardial ischemia and infarct size. Am J Cardiol (1975) 1.25
Drugs and the heart. VI. Vasodilating drugs. Lancet (1980) 1.23
Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev (2002) 1.22
Drugs and the heart. Lancet (1980) 1.21
Increased prevalence of poor sulphoxidation in patients with rheumatoid arthritis: effect of changes in the acute phase response and second line drug treatment. Ann Rheum Dis (1992) 1.20
Is a high glycogen content beneficial or detrimental to the ischemic rat heart? A controversy resolved. Circ Res (1996) 1.19
Biochemical aspects of arrhythmogenesis and ventricular fibrillation. Am J Cardiol (1979) 1.18
Incidence of acute rheumatic fever in the world: a systematic review of population-based studies. Heart (2008) 1.18
Modulation of severity of reperfusion stunning in the isolated rat heart by agents altering calcium flux at onset of reperfusion. Circ Res (1992) 1.18
Metabolic response during impending myocardial infarction. I. Relevance of studies of glucose and fatty acid metabolism in animals. Circulation (1972) 1.18
A common mitochondrial DNA variant associated with susceptibility to dilated cardiomyopathy in two different populations. Lancet (2001) 1.17
A rare variant of the leptin gene has large effects on blood pressure and carotid intima-medial thickness: a study of 1428 individuals in 248 families. J Med Genet (2005) 1.16
Coronary flow rate and perfusion pressure as determinants of mechanical function and oxidative metabolism of isolated perfused rat heart. J Physiol (1965) 1.16
Effects of substrates on tissue metabolic changes in the isolated rat heart during underperfusion and on release of lactate dehydrogenase and arrhythmias during reperfusion. Circ Res (1978) 1.16
Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolaemia. Atherosclerosis (1991) 1.14
Adjuvant corticosteroids for tuberculous pericarditis: promising, but not proven. QJM (2003) 1.14
Reduction of ischemic K+ loss and arrhythmias in rat hearts. Effect of glibenclamide, a sulfonylurea. Circ Res (1990) 1.13
Protective action of amiodarone against ventricular fibrillation in the isolated perfused rat heart. Am J Cardiol (1979) 1.13
Myocardial metabolism in ischemic heart disease: basic principles and application to imaging by positron emission tomography. Prog Cardiovasc Dis (1989) 1.13
Metabolism of triglyceride fatty acid by the perfused rat heart. Biochem J (1967) 1.12
Steroids for treating tuberculous meningitis. Cochrane Database Syst Rev (2000) 1.11
Pyruvate metabolism in the perfused rat heart. Am J Physiol (1963) 1.11
Adenosine cardioplegia. Adenosine versus potassium cardioplegia: effects on cardiac arrest and postischemic recovery in the isolated rat heart. J Thorac Cardiovasc Surg (1989) 1.09
Reduced osmolarity oral rehydration solution for treating cholera. Cochrane Database Syst Rev (2004) 1.07
Effects of free fatty acid and enzyme release in experimental glucose on myocardial infarction. Nature (1975) 1.07
Dinitrophenol, cyclosporin A, and trimetazidine modulate preconditioning in the isolated rat heart: support for a mitochondrial role in cardioprotection. Cardiovasc Res (2000) 1.07
The value of lactate and pyruvate measurements in the assessment of the redox state of free nicotinamide-adenine dinucleotide in the cytoplasm of perfused rat heart. Eur J Clin Invest (1971) 1.07
Glucose flux rate regulates onset of ischemic contracture in globally underperfused rat hearts. Circ Res (1990) 1.07
Glucose and glycogen utilisation in myocardial ischemia--changes in metabolism and consequences for the myocyte. Mol Cell Biochem (1998) 1.07
Where to practise evidence-based medicine? Lancet (2001) 1.06
Calcium channel blockers and preconditioning. J Mol Cell Cardiol (2000) 1.06
An approach to the patient with suspected pericardial disease. S Afr Med J (2016) 1.06
Cyclic AMP levels in ischaemic and non-ischaemic myocardium following coronary artery ligation: relation to ventricular fibrillation. J Mol Cell Cardiol (1978) 1.06
The inhibition of skeletal-muscle fructose 1,6-diphosphatase by adenosine monophosphate. Biochem J (1967) 1.06
Drugs and the heart four years on. Lancet (1984) 1.05
Class II correction-reducing patient compliance: a review of the available techniques. J Orthod (2000) 1.04
Novel genetic variants linked to coronary artery disease by genome-wide association are not associated with carotid artery intima-media thickness or intermediate risk phenotypes. Atherosclerosis (2008) 1.04
Ventricular arrhythmias associated with coronary artery occlusion and reperfusion in the isolated perfused rat heart: a model for assessment of antifibrillatory action of antiarrhythmic agents. Cardiovasc Res (1978) 1.04
Experimental myocardial infarction with left ventricular failure in the isolated perfused rat heart. Effects of isoproterenol and pacing. J Mol Cell Cardiol (1975) 1.04
Effect of fatty acids on contractility and rhythm of the heart. Nature (1970) 1.03
Poikiloderma, tendon contracture and pulmonary fibrosis: a new autosomal dominant syndrome? Br J Dermatol (2006) 1.03
A relationship between adenosine triphosphate, glycolysis and ischaemic contracture in the isolated rat heart. J Mol Cell Cardiol (1981) 1.02
Role of cyclic nucleotides in heart metabolism. Cardiovasc Res (1982) 1.02
Drugs and the heart. IV. Antiarrhythmic agents. Lancet (1980) 1.01
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev (2002) 1.01
The effect of alpha- and beta-adrenoceptor antagonist agents on reperfusion ventricular fibrillation and metabolic status in the isolated perfused rat heart. J Am Coll Cardiol (1983) 0.99
Does South Africa need a national clinical trials support unit? S Afr Med J (2010) 0.99
Is lactate-induced myocardial ischaemic injury mediated by decreased pH or increased intracellular lactate? J Mol Cell Cardiol (1995) 0.99
Myocardial infarct size. Part I. Basic considerations. Am Heart J (1980) 0.98
A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. Br J Pharmacol (2008) 0.98
Fluoxetine and ventricular torsade--is there a link? Int J Cardiol (1995) 0.97
Educational factors that influence the urban-rural distribution of health professionals in South Africa: a case-control study. S Afr Med J (2011) 0.97
Cyclic adenosine monophosphate, ventricular fibrillation, and antiarrhythmic drugs. Lancet (1976) 0.96
Free radical activity in type 2 diabetes. Diabet Med (1990) 0.96
Myocardial infarct size. Part 2. Comparison of anti-infarct effects of beta-blockade, glucose-insulin-potassium, nitrates, and hyaluronidase. Am Heart J (1980) 0.96
Failure of high concentrations of circulating free fatty acids to provoke arrhythmias in experimental myocardial infarction. Lancet (1971) 0.96
Opposing effects on infarction of delta and kappa opioid receptor activation in the isolated rat heart: implications for ischemic preconditioning. Basic Res Cardiol (2000) 0.95
Impaired cardiac work and oxygen uptake after reperfusion of regionally ischaemic myocardium. J Mol Cell Cardiol (1979) 0.94
Distribution of myocardial blood flow before and after coronary artery ligation in the baboon. Relation to early ventricular fibrillation. Cardiovasc Res (1974) 0.94
Adrenaline-induced "oxygen-wastage" and enzyme release from working rat heart. Effects of calcium antagonism, beta-blockade, nicotinic acid and coronary artery ligation. J Mol Cell Cardiol (1979) 0.94
Thrombotic obstruction of the Björk-Shiley valve: the Glasgow experience. Thorax (1984) 0.94
Effect of alpha-adrenoceptor antagonists (phentolamine, nicergoline and prazosin) on reperfusion arrhythmias and noradrenaline release in perfused rat heart. Br J Pharmacol (1985) 0.93
Catecholamine-induced myocardial cell damage: catecholamines or adrenochrome. J Mol Cell Cardiol (1985) 0.93